Overview Dividends

(GMAB) Genmab AS - Ratings and Ratios

Exchange: NASDAQ • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US3723032062

Antibody, Cancer, Lymphoma, Myeloma, Solid Tumors

EPS (Earnings per Share)

EPS CAGR: 79.54%
EPS Trend: 72.3%

Last SUE: 0.93σ
Qual. Beats: 2

Revenue

Revenue CAGR: -44.41%
Revenue Trend: -28.7%

Last SUE: -0.97σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	35.4%
Value at Risk 5%th	55.6%
Relative Tail Risk	-4.58%

Reward TTM
Sharpe Ratio	1.22
Alpha	44.01

Character TTM
Hurst Exponent	0.648
Beta	0.476
Beta Downside	0.535

Drawdowns 3y
Max DD	61.79%
Mean DD	37.02%
Median DD	38.94%

Description: GMAB Genmab AS October 16, 2025

Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotech firm that creates antibody-based therapeutics for oncology and a range of other diseases. Its commercial portfolio includes EPKINLY and TEPKINLY for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Tivdak for metastatic cervical cancer after chemotherapy failure. The pipeline spans multiple modalities-bispecific antibodies (e.g., epcoritamab), antibody-drug conjugates (e.g., tisotumab vedotin), and novel immune-modulating agents (e.g., Mim8 for hemophilia A)-targeting hematologic malignancies, solid tumors, and non-oncology indications such as multiple sclerosis and thyroid eye disease.

Key metrics (as of Q3 2024) show Genmab generating roughly $1.1 billion in total revenue, with ≈ $480 million coming from its partnership-driven products (e.g., DARZALEX with Janssen). R&D intensity remains high at ~ 23 % of sales, reflecting its expansive pipeline of > 30 candidates. The company’s cash runway extends through 2026, supported by long-term collaborations with AbbVie, Pfizer, Johnson & Johnson, Novartis, and others, which collectively contribute milestone payments and shared development risk.

Sector-level drivers that underpin Genmab’s outlook include the accelerating growth of the global antibody therapeutics market (CAGR ≈ 9 % through 2030) and increasing payer acceptance of bispecific and ADC platforms, which are expected to command higher pricing power relative to traditional monoclonal antibodies. Additionally, biotech financing conditions have tightened, making strategic alliances-like Genmab’s extensive partner network-a critical source of non-dilutive capital.

For a deeper, data-rich analysis of Genmab’s valuation assumptions and scenario modeling, you might find the research tools on ValueRay useful as a next step.

GMAB Stock Overview

Market Cap in USD	18,757m
Sub-Industry	Biotechnology
IPO / Inception	2009-06-01
Return 12m vs S&P 500	32.1%
Analyst Rating	4.0 of 5

GMAB Dividends

Currently no dividends paid

GMAB Growth Ratios

Metric	Value
CAGR 3y	-12.39%
CAGR/Max DD Calmar Ratio	-0.20
CAGR/Mean DD Pain Ratio	-0.33
Current Volume	1189.9k
Average Volume	1657.9k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (6.57b TTM) > 0 and > 6% of Revenue (6% = 842.4m TTM)

FCFTA 0.43 (>2.0%) and ΔFCFTA 32.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.57% (prev 164.8%; Δ -138.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.47 (>3.0%) and CFO 3.28b <= Net Income 6.57b (YES >=105%, WARN >=100%)

Net Debt (-1.62b) to EBITDA (5.96b) ratio: -0.27 <= 3.0 (WARN <= 3.5)

Current Ratio 6.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (620.7m) change vs 12m ago -4.33% (target <= -2.0% for YES)

Gross Margin 94.31% (prev 96.09%; Δ -1.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 60.15% (prev 29.25%; Δ 30.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 48.21 (EBITDA TTM 5.96b / Interest Expense TTM 119.0m) >= 6 (WARN >= 3)

Altman Z'' 10.18

(A) 0.53 = (Total Current Assets 4.47b - Total Current Liabilities 741.0m) / Total Assets 7.02b

(B) 0.57 = Retained Earnings (Balance) 4.03b / Total Assets 7.02b

(D) 3.02 = Book Value of Equity 3.84b / Total Liabilities 1.27b

Total Rating: 10.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.06

1. Piotroski 6.50pt

2. FCF Yield 2.53%

3. FCF Margin 21.33%

4. Debt/Equity 0.02

5. Debt/Ebitda -0.27

6. ROIC - WACC (= 28.24)%

7. RoE 23.97%

8. Rev. Trend -28.70%

9. EPS Trend 72.33%

What is the price of GMAB shares?

As of November 26, 2025, the stock is trading at USD 31.40 with a total of 1,189,855 shares traded.
Over the past week, the price has changed by +3.56%, over one month by +8.16%, over three months by +29.16% and over the past year by +51.03%.

Is GMAB a buy, sell or hold?

Genmab AS has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy GMAB.

Strong Buy: 4
Buy: 1
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the GMAB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	37.2	18.6%
Analysts Target Price	37.2	18.6%
ValueRay Target Price	34.3	9.3%

GMAB Fundamental Data Overview November 25, 2025

Market Cap DKK = 121.52b (18.76b USD * 6.4788 USD.DKK)
P/E Trailing = 13.3553
P/E Forward = 11.7233
P/S = 4.8774
P/B = 3.2604
P/EG = 0.7582
Beta = 0.793
Revenue TTM = 14.04b DKK
EBIT TTM = 5.74b DKK
EBITDA TTM = 5.96b DKK
Long Term Debt = 142.0m DKK (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.0m DKK (from shortTermDebt, last quarter)
Debt = 142.0m DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.62b DKK (from netDebt column, last quarter)
Enterprise Value = 118.25b DKK (121.52b + Debt 142.0m - CCE 3.41b)
Interest Coverage Ratio = 48.21 (Ebit TTM 5.74b / Interest Expense TTM 119.0m)
FCF Yield = 2.53% (FCF TTM 2.99b / Enterprise Value 118.25b)
FCF Margin = 21.33% (FCF TTM 2.99b / Revenue TTM 14.04b)
Net Margin = 46.80% (Net Income TTM 6.57b / Revenue TTM 14.04b)
Gross Margin = 94.31% ((Revenue TTM 14.04b - Cost of Revenue TTM 798.2m) / Revenue TTM)
Gross Margin QoQ = 94.32% (prev 93.84%)
Tobins Q-Ratio = 16.84 (Enterprise Value 118.25b / Total Assets 7.02b)
Interest Expense / Debt = 2.11% (Interest Expense 3.00m / Debt 142.0m)
Taxrate = 16.80% (81.0m / 482.0m)
NOPAT = 4.77b (EBIT 5.74b * (1 - 16.80%))
Current Ratio = 6.03 (Total Current Assets 4.47b / Total Current Liabilities 741.0m)
Debt / Equity = 0.02 (Debt 142.0m / totalStockholderEquity, last quarter 5.75b)
Debt / EBITDA = -0.27 (Net Debt -1.62b / EBITDA 5.96b)
Debt / FCF = -0.54 (Net Debt -1.62b / FCF TTM 2.99b)
Total Stockholder Equity = 27.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 93.58% (Net Income 6.57b / Total Assets 7.02b)
RoE = 23.97% (Net Income TTM 6.57b / Total Stockholder Equity 27.41b)
RoCE = 20.83% (EBIT 5.74b / Capital Employed (Equity 27.41b + L.T.Debt 142.0m))
RoIC = 36.00% (NOPAT 4.77b / Invested Capital 13.26b)
WACC = 7.76% (E(121.52b)/V(121.66b) * Re(7.77%) + D(142.0m)/V(121.66b) * Rd(2.11%) * (1-Tc(0.17)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.86%
[DCF Debug] Terminal Value 79.34% ; FCFE base≈3.40b ; Y1≈3.67b ; Y5≈4.52b
Fair Price DCF = 128.1 (DCF Value 78.94b / Shares Outstanding 616.0m; 5y FCF grow 8.77% → 3.0% )
EPS Correlation: 72.33 | EPS CAGR: 79.54% | SUE: 0.93 | # QB: 2
Revenue Correlation: -28.70 | Revenue CAGR: -44.41% | SUE: -0.97 | # QB: 0

Additional Sources for GMAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle